Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.65 |
| ▸ | CA1 | P00915 | 3/20 | 0.65 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856960 | 1.00 | CA2 (0.65) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3452084 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7209672 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL276768 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7212250 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL490747 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3855790 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3861238 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL1672036 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7204823 | 0.98 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678468-B | 5, 6-fused bicyclic compounds and compositions thereof for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-117679415-A | Glucoamide synthase inhibitors | 建新公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-108700594-B | Biomarkers for polycystic kidney disease and uses thereof | 建新公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-110643835-B | Extraction system, extraction method and application for separating magnesium from magnesium-containing brine by using secondary amide solvent to extract lithium | 湘潭大学 | 2021-04-20 | — | — | CN | disclosed |
| CN-107080747-B | Glucosylceramide synthase inhibitors | 建新公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020201816-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING | UNIVERSITY OF HONG KONG (CN) | 2020-10-08 | — | — | WO | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1165559-A1 | 1,4-DIAZABICYCLO[3.2.2]NONANE-4-CARBOXYLATE AND CARBOXAMIDE DERIVATIVES, PRODUCTION AND USE THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058311-A1 | 1,4-DIAZABICYCLO[3.2.2]NONANE-4-CARBOXYLATE AND CARBOXAMIDE DERIVATIVES, PRODUCTION AND USE THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | CA2 94/4885CA1 194/4885GRIK1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.